Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Primo N Lara

Showing results (71-80 of 274) with videos related to

Pageof 28
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2020
Framing Pragmatic Strategies to Reduce Mortality From Bladder Cancer: An Endorsement From the Society of Urologic OncologyRalph de Vere White, Primo N Lara, Peter C Black, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2015
Squamous cell lung cancer: from tumor genomics to cancer therapeuticsDavid R Gandara, Peter S Hammerman, Martin L Sos, et al.
The Journal of Urology|December 23, 2008
Predictors of survival of advanced renal cell carcinoma: long-term results from Southwest Oncology Group Trial S8949Primo N Lara, Catherine M Tangen, Sarah J Conlon, et al.
Cancer|March 20, 2014
Twenty years post-NIH Revitalization Act: enhancing minority participation in clinical trials (EMPaCT): laying the groundwork for improving minority clinical trial accrual: renewing the case for enhancing minority participation in cancer clinical trialsMoon S Chen, Primo N Lara, Julie H T Dang, et al.
Journal of Cancer Research and Clinical Oncology|October 18, 2014
Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell linesWilliam S Holland, Danielle C Chinn, Primo N Lara, et al.
Lung Cancer (Amsterdam, Netherlands)|December 2, 2017
Clinical predictors of survival in young patients with small cell lung cancer: Results from the California Cancer RegistryJoshua D Lara, Ann Brunson, Jonathan W Riess, et al.
Clinical Lung Cancer|June 28, 2006
Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancerAngela M Davies, Cheryl Ho, Primo N Lara, et al.
European Urology|April 29, 2008
Current applications for prostate-specific antigen doubling timeMichelle L Ramírez, Eric C Nelson, Ralph W Devere White, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|April 3, 2020
Current Approaches to the Treatment of Advanced or Metastatic Renal Cell CarcinomaMatthew Tenold, Praful Ravi, Monika Kumar, et al.
Clinical Lung Cancer|January 14, 2017
Evolution and Increasing Complexity of the Therapeutic Landscape in Advanced Non-Small-cell Lung CancerDavid R Gandara, Jonathan W Riess, Karen Kelly, et al.
Pageof 28

Showing results (71-80 of 274) with videos related to

Sort By:
Pageof 28
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2020
Framing Pragmatic Strategies to Reduce Mortality From Bladder Cancer: An Endorsement From the Society of Urologic OncologyRalph de Vere White, Primo N Lara, Peter C Black, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2015
Squamous cell lung cancer: from tumor genomics to cancer therapeuticsDavid R Gandara, Peter S Hammerman, Martin L Sos, et al.
The Journal of Urology|December 23, 2008
Predictors of survival of advanced renal cell carcinoma: long-term results from Southwest Oncology Group Trial S8949Primo N Lara, Catherine M Tangen, Sarah J Conlon, et al.
Cancer|March 20, 2014
Twenty years post-NIH Revitalization Act: enhancing minority participation in clinical trials (EMPaCT): laying the groundwork for improving minority clinical trial accrual: renewing the case for enhancing minority participation in cancer clinical trialsMoon S Chen, Primo N Lara, Julie H T Dang, et al.
Journal of Cancer Research and Clinical Oncology|October 18, 2014
Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell linesWilliam S Holland, Danielle C Chinn, Primo N Lara, et al.
Lung Cancer (Amsterdam, Netherlands)|December 2, 2017
Clinical predictors of survival in young patients with small cell lung cancer: Results from the California Cancer RegistryJoshua D Lara, Ann Brunson, Jonathan W Riess, et al.
Clinical Lung Cancer|June 28, 2006
Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancerAngela M Davies, Cheryl Ho, Primo N Lara, et al.
European Urology|April 29, 2008
Current applications for prostate-specific antigen doubling timeMichelle L Ramírez, Eric C Nelson, Ralph W Devere White, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|April 3, 2020
Current Approaches to the Treatment of Advanced or Metastatic Renal Cell CarcinomaMatthew Tenold, Praful Ravi, Monika Kumar, et al.
Clinical Lung Cancer|January 14, 2017
Evolution and Increasing Complexity of the Therapeutic Landscape in Advanced Non-Small-cell Lung CancerDavid R Gandara, Jonathan W Riess, Karen Kelly, et al.
Pageof 28